Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, Xiangdong Zhou et al.|The Lancet Oncology|2017Cited by 1.2k
Akt1 Enhances CA916798 Expression through mTOR PathwayYuliang Wang, Xiangdong Zhou|PLoS ONE|2013Cited by 10
Long non-coding RNA ZNF674-AS1 regulates miR-23a/E-cadherin axis to suppress the migration and invasion of non-small cell lung cancer cellsJie Wang, Xiangdong Zhou|Translational Cancer Research|2021Cited by 7